Aldosterone antagonists for people with chronic kidney disease requiring dialysis

This review aims to assess the benefits and harms of aldosterone antagonists, both non-selective (spironolactone) and selective (eplerenone), in comparison to placebo or no intervention or standard care in people with ESKD requiring haemodialysis or peritoneal dialysis.

This is a protocol.